期刊文献+

肺癌患者外周血肿瘤异常蛋白的表达及临床意义 被引量:5

Expression and significance of tumor abnormal protein in peripheral blood of patients with lung cancer
在线阅读 下载PDF
导出
摘要 目的探讨肿瘤异常蛋白(TAP)在肺癌组织中的表达情况及其与患者临床特征的关系和临床意义。方法选取125例初治肺癌患者作为肺癌组,选取同期体检的120例健康者作为健康对照组。检测两组研究对象外周血中TAP的相对表达水平,并评价其在肺癌中的临床价值。结果肺癌组患者肺癌组织中TAP的阳性表达率为66.4%(83/125),明显高于健康对照组健康者正常组织中的15.0%(18/120),差异有统计学意义(P<0.01)。Ⅲ+Ⅳ肺癌组织中的TAP的阳性表达率明显高于Ⅰ+Ⅱ期肺癌组织中的TAP的阳性表达率,差异有统计学意义(P<0.01);不同性别、年龄、组织学分型肺癌患者的肺癌组织中TAP的阳性表达率比较,差异均无统计学意义(P>0.05)。结论 TAP检测可以作为肺癌诊断的辅助方法,可与其他指标共同对肺癌进行筛查。 Objective To investigate the expression of tumor abnormal protein (TAP) in lung cancer, its relationship with clinical characteristics of patients and its clinical significance.Method One hundred and twenty-five patients firstly diagnosed as lung cancer were recruited as lung cancer group, and 120 healthy subjects undertaking physical examination in the out-patient department were collected as healthy control group. The expression of TAP in peripheral blood was examined, and the clinical value in lung cancer was evaluated.Result The positive expression rate of TAP in lung cancer patients (66.4%, 83/125) was significantly higher than that in healthy subjects (15.0%, 18/120), and the differences were statistically significant (P〈0.01). The positive expression rate of TAP in patients of stage III+IV lung cancer was significantly higher than that in patients of stage I+II, and the differences were statistically significant (P〈0.01). There was no significant difference in the positive expression rate of TAP among patients with different sex, age and histological classi- fication (P〉0.05). Conclusion TAP can be used as an auxiliary method for the diagnosis of lung cancer, and can be a screen marker for lung cancer combined with other indicators.
作者 徐瑞彤 徐艳玲 王彤 成红艳 戴冠群 XU Ruitong;XU Yanling;WANG Tong;CHENG Hongyan;DAI Guanqun(Department of General Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu,China)
出处 《癌症进展》 2018年第13期1644-1646,共3页 Oncology Progress
关键词 肿瘤异常蛋白 肿瘤标志物 肺癌 诊断 tumor abnormal protein tumor marker lung cancer diagnosis
  • 相关文献

二级参考文献30

  • 1International Agency for Research on Cancer. GLOBOCANproject. Accessed 20 June 2014. Available from: URL: http://globocan.iarc.fr.
  • 2Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T,Murano T, Fukuda H, Iinuma T, Uno K, Nishizawa S, TsukamotoE, Iwata H, Inoue T, Oguchi K, Nakashima R, Inoue T. The currentstatus of an FDG-PET cancer screening program in Japan, basedon a 4-year (2006-2009) nationwide survey. Ann Nucl Med 2013;27: 46-57 [PMID: 23086544 DOI: 10.1007/s12149-012-0660-x].
  • 3Sehdev A, Catenacci DV. Gastroesophageal cancer: focus onepidemiology, classification, and staging. Discov Med 2013; 16:103-111 [PMID: 23998446].
  • 4Coupe NA, Karikios D, Chong S, Yap J, Ng W, Merrett N, Lin M.Metabolic information on staging FDG-PET-CT as a prognostictool in the evaluation of 97 patients with gastric cancer. AnnNucl Med 2014; 28: 128-135 [PMID: 24297388 DOI: 10.1007/s12149-013-0791-8].
  • 5Smyth EC, Shah MA. Role of 1-F 2-fluoro-2-deoxyglucosepositron emission tomography in upper gastrointestinalmalignancies. World J Gastroenterol 2011; 17: 5059-5074 [PMID:22171140 DOI: 10.3748/wjg.v17.i46.5059].
  • 6Makis W, Ciarallo A, Hickeson M, Rush C, Derbekyan V,Novales-Diaz JA, Laufer J, Stern J, Lisbona R. Spectrum ofgastric malignancy on 18F-FDG PET/CT: a pictorial essay. ClinImaging 2012; 36: 432-446 [PMID: 22920343 DOI: 10.1016/j.clinimag.2011.12.014].
  • 7Namikawa T, Okabayshi T, Nogami M, Ogawa Y, Kobayashi M,Hanazaki K. Assessment of (18)F-fluorodeoxyglucose positronemission tomography combined with computed tomography inthe preoperative management of patients with gastric cancer. Int JClin Oncol 2014; 19: 649-655 [PMID: 23877653 DOI: 10.1007/s10147-013-0598-6].
  • 8Park JC, Lee JH, Cheoi K, Chung H, Yun MJ, Lee H, Shin SK,Lee SK, Lee YC. Predictive value of pretreatment metabolicactivity measured by fluorodeoxyglucose positron emissiontomography in patients with metastatic advanced gastric cancer:the maximal SUV of the stomach is a prognostic factor. Eur J NuclMed Mol Imaging 2012; 39: 1107-1116 [PMID: 22526958 DOI:10.1007/s00259-012-2116-x].
  • 9Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, Lee MH,Kim JH, Lee SY, Sung IK, Park HS, Yoo MW, Lee KY. HighFDG uptake in PET/CT predicts worse prognosis in patientswith metastatic gastric adenocarcinoma. J Cancer Res ClinOncol 2010; 136: 1929-1935 [PMID: 20306088 DOI: 10.1007/s00432-010-0852-5].
  • 10Kim YH, Choi JY, Do IG, Kim S, Kim BT. Factors affecting18F-FDG uptake by metastatic lymph nodes in gastric cancer. JComput Assist Tomogr 2013; 37: 815-819 [PMID: 24045262 DOI:10.1097/RCT.0b013e3182972989].

共引文献2

同被引文献32

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部